Clinical Research Directory
Browse clinical research sites, groups, and studies.
Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
Sponsor: EBG MedAustron GmbH
Summary
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
Official title: Phase II Trial of Hypo-fractionated Highly Conformal Radiotherapy for Locally Advanced Pancreatic Carcinomas
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2022-05-16
Completion Date
2028-12
Last Updated
2026-03-20
Healthy Volunteers
No
Conditions
Interventions
Particle-therapy using protons or carbon ions
According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
Blood sampling
Evaluation before treatment-start, after treatment and follow-up period.
Magnetic resonance imaging
For treatment planning as well as for follow-up radiological tumor assessment.
Computertomography
For treatment planning as well as for follow-up radiological tumor assessment.
18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)
For treatment planning as well as for follow-up radiological tumor assessment.
Locations (1)
EBG MedAustron GmbH
Wiener Neustadt, Lower Austria, Austria